MEDICINOVA, INC.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Sep 2023 | Sep 2021 | Mar 2021 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $458.4K | $187.0K | $123.3K | $134.6K | $1.0M | $37.5K | $4.0M | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $900.0K | $1.2M | $1.5M | $2.0M | $700.0K | $2.0M | $2.0M | $600.0K |
| SG&A Expense | $1.8M | $1.6M | $1.8M | $1.4M | $1.4M | $1.6M | $2.1M | $1.5M |
| Operating Income | $-2.5M | $-2.8M | $-3.4M | $-3.6M | $-1.1M | $-3.6M | $-201.5K | $-2.2M |
| Operating Margin | -554.3% | -1,516.6% | -2,741.7% | -2,679.9% | -114.7% | -9,605.2% | -5.0% | — |
| Interest Expense | — | — | — | — | — | — | — | $140 |
| Pretax Income | — | — | — | — | — | — | — | $-2.2M |
| Income Tax Expense | — | — | — | — | — | — | — | $2.9K |
| Net Income | $-2.3M | $-2.6M | $-3.1M | $-3.3M | $-723.1K | $-3.6M | $-187.8K | $-2.2K |
| Net Margin | -504.8% | -1,383.1% | -2,473.6% | -2,437.7% | -72.3% | -9,544.4% | -4.7% | — |
| EPS (Basic) | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.01 | $-0.07 | $0.00 | $-0.09 |
| EPS (Diluted) | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.01 | $-0.07 | $0.00 | $-0.09 |
| Shares Outstanding (Basic) | 49.2M | 49.2M | 49.0M | 49.0M | 49.0M | 49.0M | 48.8M | 24.6M |
| Shares Outstanding (Diluted) | 49.2M | 49.2M | 49.0M | 49.0M | 49.0M | 49.0M | 48.8M | 24.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |